pentobarbital will lessen the extent or influence of guanfacine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Solid or reasonable CYP3A4 inducers considerably decrease guanfacine plasma concentrations and elimination 50 %-everyday living.

pentobarbital will reduce the level or impact of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.

pentobarbital will reduce the level or outcome of theophylline by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

pentobarbital will lower the extent or result of sildenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Powerful CYP3A4 inducers are anticipated to bring about substantial decreases in sildenafil plasma degrees

Remark: Barbiturates may perhaps maximize adverse effects, including respiratory depression, made by harmful doses of TCAs. With therapeutic doses of TCAs, barbiturates maximize metabolism and reduce blood concentrations of TCAs.

pentobarbital will minimize the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

pentobarbital will lessen the extent or outcome of sufentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Not known.

pentobarbital will lower the level or outcome of nelfinavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.

pentobarbital website decreases amounts of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Steer clear of or Use Alternate Drug. Keep away from Except the coadministration outweighs the possible threat of ponatinib underexposure; monitor for indications of diminished efficacy.

pentobarbital will lessen the extent or influence of diclofenac by impacting hepatic enzyme CYP2C9/ten metabolism. Slight/Significance Unknown.

pentobarbital will minimize the extent or impact of fentanyl transdermal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead to the lessen in fentanyl plasma concentrations, insufficient efficacy or, probably, development of the withdrawal syndrome within a patient who may have designed physical dependence to fentanyl.

Watch Closely (3)pentobarbital will lower the extent or outcome of diazepam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check. Potent or moderate CYP3A4 inducers might enhance rate of diazepam elimination; as a result, efficacy of diazepam can be lessened.

pentobarbital will minimize the extent or result of nimodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.

Contraindicated (1)pentobarbital decreases levels of vandetanib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Prevent coadministration with potent CYP3A4 inducers; these drugs reduce publicity to vandetanib by approximately 40%.